KRAS and lung cancer: The latter becomes particularly relevant in the context of lung cancer, with recent publications reporting that KRAS-mutant NSCLC tumors rely on non-canonical integrin/FAK [45] and ATM-related signaling [8] to drive cell proliferation, epithelial-to-mesenchymal transition, invasion, and resistance to conventional DNA damaging therapies.